Newm-035 -

Below is an overview of the development and science behind . TRG-035: The World's First Tooth Regrowth Drug

: Success in Phase I will lead to trials for children aged 2–7 with congenital anodontia (being born without a full set of teeth). Future Outlook NEWM-035

The drug was developed by , a spinoff from Kyoto University, led by Dr. Katsu Takahashi. Below is an overview of the development and science behind

: Preclinical trials on mice and ferrets—chosen for their similar dental structures—successfully produced new teeth with normal enamel and root structures and no significant side effects. a spinoff from Kyoto University